Mabwell (Shanghai) Bioscience , Ltd. PEG Ratio

The latest PEG ratio for 688062.SS is -138.04. That is below the Healthcare sector average of 0.46. Investors often review this figure alongside Mabwell (Shanghai) Bioscience , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, 688062.SS currently prints -138.04 for PEG ratio, while the sector average sits near 0.46. That is roughly 29877.9% below the sector mean. Large gaps often invite a closer look at Mabwell (Shanghai) Bioscience , Ltd.'s growth, margins, and balance sheet.

A PEG ratio of -138.04 for Mabwell (Shanghai) Bioscience , Ltd. is not 'good' or 'bad' on its own. Compare it with the peer average (0.46) and with 688062.SS's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting 688062.SS's PEG ratio (-138.04), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Mabwell (Shanghai) Bioscience , Ltd.'s PEG ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.